Last reviewed 2026-04-20 · How we verify

Acamylophenine (CAMYLOFIN)

Phase 2 active Small molecule Quality 28/100

Acamylophenine (generic name: CAMYLOFIN) is a camylofin drug. It is currently in Phase 2 development.

Camylofin works by binding to and modulating the activity of the solute carrier family 22 member 1 protein.

Acamylophenine, also known as Camylofin, is a small molecule drug that targets the solute carrier family 22 member 1. It is classified as a camylofin drug, but its commercial status and approved indications are unknown. The mechanism of action of Camylofin is not well-documented, but it is believed to work by modulating the activity of its target protein. Further research is needed to fully understand its therapeutic potential and safety profile.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CAMYLOFIN
Drug class	camylofin
Target	Solute carrier family 22 member 1
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Camylofin is the key that binds to a specific protein, called solute carrier family 22 member 1, and helps to regulate its activity. This can have a variety of effects on the body, depending on the specific protein and its role in different cells and tissues.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acamylophenine CI brief — competitive landscape report
Acamylophenine updates RSS · CI watch RSS

Frequently asked questions about Acamylophenine

What is Acamylophenine?

Acamylophenine (CAMYLOFIN) is a camylofin drug.

How does Acamylophenine work?

Camylofin works by binding to and modulating the activity of the solute carrier family 22 member 1 protein.

What is the generic name of Acamylophenine?

CAMYLOFIN is the generic (nonproprietary) name of Acamylophenine.

What drug class is Acamylophenine in?

Acamylophenine belongs to the camylofin class. See all camylofin drugs at /class/camylofin.

What development phase is Acamylophenine in?

Acamylophenine is in Phase 2.

What does Acamylophenine target?

Acamylophenine targets Solute carrier family 22 member 1 and is a camylofin.

Drug class: All camylofin drugs
Target: All drugs targeting Solute carrier family 22 member 1
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing